Trends in the Administration of Tranexamic Acid for Postpartum Hemorrhage

Recruiting now

Conditions studied: Postpartum Hemorrhage, Delivery Complication, Cesarean Section Complications, Perinatal Problems

In brief

Postpartum hemorrhage (PPH) is the global leading cause of maternal death, with 20-30% of maternal deaths in Thailand linked to hemorrhage. The WOMAN Trial (2017) provided strong evidence that administering tranexamic acid (TXA)within three hours of bleeding onset lowered PPH-related mortality by 31%. Consequently, the World Health Organization (WHO) updated its guidelines, recommending TXA as part of the standard treatment package for all PPH cases. Following this, the use of TXA has been widely adopted globally and increased in Thailand. A recent study at a major Thai university hospital observed a significant increase in TXA administration after 2017. The current study aims to further analyze the recent growth rate of TXA use and its impact on obstetric and perinatal outcomes during cesarean deliveries with PPH.

Key facts

Study ID

NCT07278037

Run by

Mahidol University

People needed

648

Starts

2025-12-01

Expected to finish

2026-09-30

Last updated by the study team

2025-12-22

Who can join

Age: any. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• 1. Patients underwent cesarean delivery with primary postpartum hemorrhage

You may not qualify if…

• Gestational age at less than 24 weeks
• Absence of the anesthetic record
• Received tranexamic acid in the antepartum period
• Blood loss less than 1,000 ml

Where it is running

• Siriraj Hospital — Bangkoknoi, Bangkok, Thailand (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.